Skip to main content

Improving PTSD May Also Improve Diabetes Outcomes

Medically reviewed by Carmen Pope, BPharm. Last updated on Aug 15, 2024.

By Lori Solomon HealthDay Reporter

THURSDAY, Aug. 15, 2024 -- No longer meeting diagnostic criteria for posttraumatic stress disorder (PTSD) is associated with a lower risk for poor diabetes outcomes, particularly among younger veterans, according to a study published online Aug. 13 in JAMA Network Open.

Jeffrey F. Scherrer, Ph.D., from the Saint Louis University School of Medicine, and colleagues examined the association between meeting diagnostic criteria for PTSD and risk for poor type 2 diabetes (T2D) outcomes among 10,002 veterans.

The researchers found that before controlling for confounding with entropy balancing, patients who no longer met PTSD diagnostic criteria had similar incidence rates for starting insulin (22.4 versus 24.4 per 1,000 person-years), poor glycemic control (137.1 versus 133.7 per 1,000 person-years), any microvascular complication (108.4 versus 104.8 per 1,000 person-years), and all-cause mortality (11.2 versus 11.0 per 1,000 person-years) compared with patients with persistent PTSD. However, when controlling for confounding, there was a lower risk for microvascular complications (hazard ratio [HR], 0.92) among those no longer meeting PTSD criteria. For younger veterans (ages 18 to 49 years), no longer meeting PTSD criteria was associated with a lower risk for insulin initiation (HR, 0.69) and all-cause mortality (HR, 0.39). No longer meeting PTSD criteria was also associated with a lower risk for insulin initiation among patients without depression (HR, 0.73).

"The findings of this study suggest that PTSD is a modifiable risk factor for some adverse T2D outcomes among patients with comorbid PTSD and T2D," the authors write.

Abstract/Full Text

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2025 HealthDay. All rights reserved.

Posted August 2024

Read this next

Many Medicaid Enrollees Have Restricted Access to SGLT2 Inhibitors, GLP-1 Receptor Agonists

WEDNESDAY, April 30, 2025 -- Many Medicaid enrollees with type 2 diabetes have restricted access to cardioprotective medications, including sodium-glucose cotransporter-2...

Sodium-Glucose Cotransporter 2 Inhibitors Increase Risk for Falls in Patients With Diabetes

WEDNESDAY, April 30, 2025 -- Sodium-glucose cotransporter 2 (SGLT2) inhibitor use is an independent risk factor for falls in people with type 2 diabetes, according to a study...

GLP-1 RAs, SGLT2 Inhibitors May Reduce Risk for Alzheimer Disease, Dementia in T2DM

THURSDAY, April 17, 2025 -- Both glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT2is) are associated with a reduced risk...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.